Carrick Therapeutics

Carrick Therapeutics is a clinical-stage biopharmaceutical company focused on building the future of oncological therapy to improve patient outcomes. Its corporate headquarters is in Boston, Massachusetts. The company translates in-house and in-licensed assets to target the most aggressive and resistant forms of cancer, and its therapies are designed to work in combination with existing oncology drugs to target advanced breast, prostate and ovarian cancers, with further potential in pancreatic and Ewing's sarcoma. Its two lead programs are a CDK7 inhibitor and a CDK12/13 inhibitor/Cyclin-K degrader.

Carrick Therapeutics is a clinical-stage biopharmaceutical company focused on building the future of oncological therapy to improve patient outcomes. The company's corporate headquarters is in Boston, Massachusetts. The name Carrick means 'rock' in Irish, which reflects its Irish heritage and strong foundation of like-minded scientists, collaborators and investors, and the vision to build a durable world-class company. The company translates in-house and in-licensed assets to target the most aggressive and resistant forms of cancer, working with Pharma partners, a network of clinicians and scientists across research institutions and hospitals. Its two lead programs are a CDK7 inhibitor and a CDK12/13 inhibitor/Cyclin-K degrader, which affect multiple pathways implicated in breast, prostate, ovarian, pancreatic and other types of cancer. Timothy Pearson was appointed CEO of Carrick in July 2019.

First-in-class and best-in-class oncology therapies targeting aggressive and resistant cancers.

• Samuraciclib

  CDK7 inhibitor in clinical studies.

• CT7439

  CDK12/13 inhibitor.

1. 1Carrick Therapeutics, Inc.carricktherapeutics.com
2. 2About :: Carrick Therapeutics, Inc.carricktherapeutics.com
3. 3Management Team :: Carrick Therapeutics, Inc.carricktherapeutics.com
4. 4Collaborators & Advisors :: Carrick Therapeutics, Inc.carricktherapeutics.com
5. 5Carrick Therapeutics (United States)wikidata.org